7 completed, 2 active not recruiting. 8 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 7, Active not recruiting 1 |
| Phase 3 | 2 | Active not recruiting 2 |
Follow Rifafour: new trials by email Literature Review of Rifafour trials Research Report on Rifafour
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Pan-TB Regimen Targeting Host and Microbe Sutezolid, N-acetyl cysteine, Pretomanid - Tuberculosis | Phase 2 / Phase 3 | Active not recruiting | The Aurum Institute NPC | 352 | 2023-07-28 | 2025-05-28 |
| Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB Delamanid, Bedaquiline, RHEZ - Pulmonary TB | Phase 2 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 122 | 2022-04-12 | 2026-08-12 |
| Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis Rifampin, Levofloxacin, Rifampicin, Pyrazinamide, Ethambutol and Isoniazid - Disseminated Tuberculosis, HIV | Phase 3 | Active not recruiting | University of Cape Town | 732 | 2021-08-11 | 2026-01-06 |
| Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB Meropenem Injection, Amoxicillin Clavulanate, Pyrazinamide - Tuberculosis | Phase 2 | Completed | TASK Applied Science | 22 | 2020-08-17 | 2022-01-25 |
| StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis Pravastatin, Rifafour, Vitamin B6 - Tuberculosis, Pulmonary Tuberculosis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 16 | 2020-02-21 | 2023-09-18 |
| Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) TMC207 (J), PA-824 (PA), pyrazinamide (Z) - Pulmonary Tuberculosis | Phase 2 | Completed | Global Alliance for TB Drug Development | 105 | 2012-10-01 | 2016-12-13 |
| Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002) Moxifloxacin (M), Pretomid (Pa), Pyrazinamide (Z) - Pulmonary Tuberculosis | Phase 2 | Completed | Global Alliance for TB Drug Development | 207 | 2012-03-01 | 2018-06-28 |
| Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB Rifampicin - Pulmonary Tuberculosis (TB) | Phase 2 | Completed | Radboud University Medical Center | 128 | 2011-06-01 | 2018-11-26 |
| Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001) PA-824, Pyrazinamide, TMC207 - Pulmonary Tuberculosis | Phase 2 | Completed | Global Alliance for TB Drug Development | 85 | 2010-10-01 | 2017-02-28 |
Tuberculosis (6) · Tuberculosis, Pulmonary (6)
Global Alliance for TB Drug Development (3) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Radboud University Medical Center (1) · TASK Applied Science (1) · The Aurum Institute NPC (1) · University of Cape Town (1)
South Africa (9) · Tanzania (2) · Mozambique (1)
Andreas Diacon, MD (2) · Rodney Dawson, MD (2) · Andreas Diacon (1) · Martin Boeree, MD, PhD (1) · Neil Martinson, MD, MPH (1) · Petros C. Karakousis, MD (1) · Professor Robert Wallis, MD (1) · Richard E. Chaisson, MD (1) · Rob Aarnoutse, PharmD, PhD (1) · Veronique R De Jager, MBChB (1)
PMID 22828481, PMID 25622149, PMID 25654354, PMID 25795076, PMID 29718390, PMID 33542056, PMID 38243296, PMID 38720383, PMID 41749341, PMID 42214407